NORWOOD, Mass.--(BUSINESS WIRE)--Aspect Medical Systems, Inc. (NASDAQ: ASPM) today announced that two companion articles highlighting results from the BRITE-MD (Biomarkers for Rapid Identification of Treatment Effectiveness trial in Major Depression) were published in the September issue of the journal Psychiatry Research. The BRITE trial results demonstrate that Aspect’s EEG-based Antidepressant Treatment Response (ATR) indicator is a significant predictor of patient response and remission after one week of treatment with the commonly prescribed antidepressant escitalopram. Retrospective analysis of BRITE data also suggests that ATR has the potential to positively impact depression treatment outcomes by helping clinicians select the most effective antidepressant for each patient early in their treatment.
